Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

385293

	registered interest
	date	24/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the total value of projected savings to be made by removing drugs and indications from the Cancer Drugs Fund in England over (1) Q1 of 2015–16, and (2) the whole of 2015–16.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL776
	answer	answer is ministerial correction date of answer 02/07/2015 answer text <p> </p><p /> <p>NHS England has advised that the projected value of savings from the Cancer Drugs Fund, as a result of removing drugs from the national list, is not yet available.</p><p /> <p> </p><p /> <p> </p><p /> <p> </p><p /> <p>Decisions to de-list drugs were made taking account of the need to ensure the limited resources of the Fund are used most effectively. Advances in medical science mean that new and exciting cancer medicines are emerging all the time and we want people to have access to these too.</p><p /> <p> </p><p /> <p> </p><p /> <p> </p><p /> <p>The Government established the Cancer Drugs Fund to ensure that cancer patients in England have better access to life-extending and improving drugs not routinely funded by the National Health Service.</p><p /> <p> </p><p /> <p> </p><p /> <p> </p><p /> <p>Between October 2010 and March 2015, the Fund has helped over 72,000 cancer patients.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 02/07/2015 15:54:13 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

433383

	registered interest
	date	01/12/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Brighton and Sussex University Hospitals NHS Trust
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what action they are taking to ensure that the Brighton and Sussex University Hospitals NHS Trust deals effectively with the issues of racial discrimination and harassment identified by the Care Quality Commission.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL4101
	answer	answer is ministerial correction date of answer 09/12/2015 answer text <br /><p>The NHS Trust Development Authority (TDA) is monitoring and working closely with Brighton and Sussex University Hospitals NHS Trust to support the Trust to address these issues.</p><br /><p>We are advised by the TDA that the Trust’s Race Equality Workforce Engagement Strategy involves multiple work streams led by area specific engagement groups to address specific issues and challenges across all areas and levels of the Trust. It was launched at the joint Black and Minority Ethnic (BME) Network and Trust conference in October 2014.</p><br /><p>A programme board was established and the first meeting was in February 2015. Programme board meetings are co-chaired by the Chief Executive and the Chair of the BME Network in order to provide oversight, performance management and governance of the race equality action plans developed by the various engagement groups.</p><br /><p>We are assured by the TDA that the Trust followed procedures correctly in appointing the Chairman of the Trust to hear a right of appeal from nine BME members of staff against the decision of Henrietta Hill QC.</p> answering member printed Lord Prior of Brampton question first answered 09/12/2015 12:15:13 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

166093

	registered interest
	date	25/11/2014
	answering body	Department for Work and Pensions
	answering dept id	29
	answering dept short name	Work and Pensions
	answering dept sort name	Work and Pensions
	hansard heading	Employment: Hearing Impairment
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what was the average financial value of awards made to people whose primary medical condition was classified as difficulty in hearing for the provision of a communication support worker in each of the last five years for which figures are available.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL3151
	answer	answer is ministerial correction date of answer 01/12/2014 answer text <p /> <p>The average figures for the last five years for awards for the provision of Communication Support Workers from the Access to Work scheme are:</p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>Average award</p></td></tr><tr><td><p>2009/10</p></td><td><p>£9,900</p></td></tr><tr><td><p>2010/11</p></td><td><p>£11,100</p></td></tr><tr><td><p>2011/12</p></td><td><p>£12,700</p></td></tr><tr><td><p>2012/13</p></td><td><p>£14,600</p></td></tr><tr><td><p>2013/14</p></td><td><p>£13,500</p></td></tr></tbody></table><p> </p><p>The above figures relate to the provision of Communication Support Workers only and do not include information regarding the provision of BSL interpreters.</p> answering member printed Lord Freud question first answered 01/12/2014 15:24:12 answering member 3893 label Biography information for Lord Freud
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

39768

	registered interest
	date	24/02/2014
	answering body	Cabinet Office
	answering dept id	53
	answering dept short name
	answering dept sort name
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what is their policy on the relocation of civil servants from London and the South-East of England to other regions of the country.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL5482
	answer	answer is ministerial correction date of answer 10/03/2014 answer text <p> </p><p>Relocation of Government staff outside of London and the South East continues to be considered, amongst other options, to deliver the savings set out at the Spending Review and increase the efficiency of the Government&rsquo;s estate. Reducing and rationalising the estate could result in relocations, although there is no centrally driven relocation target to this effect. Workforce planning is primarily the responsibility of each individual Department to determine.</p><p> </p> answering member printed Lord Wallace of Saltaire grouped question UIN HL5483 HL5484 question first answered 10/03/2014 12:00:00 answering member 1816 label Biography information for Lord Wallace of Saltaire
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

39769

	registered interest
	date	24/02/2014
	answering body	Cabinet Office
	answering dept id	53
	answering dept short name
	answering dept sort name
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many civil servants have been transferred from London and the South-East of England to other regions of the country since May 2010.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL5483
	answer	answer is ministerial correction date of answer 10/03/2014 answer text <p> </p><p>Relocation of Government staff outside of London and the South East continues to be considered, amongst other options, to deliver the savings set out at the Spending Review and increase the efficiency of the Government&rsquo;s estate. Reducing and rationalising the estate could result in relocations, although there is no centrally driven relocation target to this effect. Workforce planning is primarily the responsibility of each individual Department to determine.</p><p> </p> answering member printed Lord Wallace of Saltaire grouped question UIN HL5482 HL5484 question first answered 10/03/2014 12:00:00 answering member 1816 label Biography information for Lord Wallace of Saltaire
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

39770

	registered interest
	date	24/02/2014
	answering body	Cabinet Office
	answering dept id	53
	answering dept short name
	answering dept sort name
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many civil servants have been transferred from London and the South-East of England to the West Midlands since May 2010.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL5484
	answer	answer is ministerial correction date of answer 10/03/2014 answer text <p> </p><p>Relocation of Government staff outside of London and the South East continues to be considered, amongst other options, to deliver the savings set out at the Spending Review and increase the efficiency of the Government&rsquo;s estate. Reducing and rationalising the estate could result in relocations, although there is no centrally driven relocation target to this effect. Workforce planning is primarily the responsibility of each individual Department to determine.</p><p> </p> answering member printed Lord Wallace of Saltaire grouped question UIN HL5482 HL5483 question first answered 10/03/2014 12:00:00 answering member 1816 label Biography information for Lord Wallace of Saltaire
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

173011

	registered interest
	date	12/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they are taking to ensure that patients in England have access to cancer-related molecular testing.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL4083
	answer	answer is ministerial correction date of answer 26/01/2015 answer text <p><em>Improving Outcomes: a Strategy for Cancer</em> (Department of Health, 2011) did include a specific commitment to develop a commissioning and funding structure which would enable the efficient delivery of high quality molecular diagnostic testing through centres of excellence. The first phase of this work included the establishment of the Human Genomics Strategy Group (HGSG). NHS England drew upon the work of the HGSG, specifically the report <em>Building on our Inheritance; Genomic technology in healthcare</em> (2012), in the production of the proposed genetics laboratory service specification.</p><p> </p><p> </p><p> </p><p>Since 2011, the field of genetic medicine and genomics has progressed rapidly with many molecular tests now available locally. Further work is underway to better understand the specific responsibilities of NHS England as a direct commissioner of specialised services, clarify the legacy arrangements of how such tests are currently commissioned and ensure alignment with the National Tariff payment rules. This may highlight the need to develop specific commissioning policies, or undertake other commissioning interventions, that will support the continued diffusion of such technology across the National Health Service.</p><p> </p><p> </p><p> </p><p>Molecular diagnostics for cancer is the responsibility of a range of commissioners, and historically many of these tests have been funded in a number of different ways including by industry (i.e., have been free to the NHS). The legacy work may highlight a need for NHS England to undertake commissioning interventions, which could include the development of specific commissioning policies or pricing work.</p><p> </p><p> </p><p> </p><p>Funding for these molecular tests is complex. At this stage, the earliest opportunity for changes to be made to the National Tariff, should such action be thought to be necessary, is now 2016-17 with consultation on any proposals being launched in summer 2015.</p><p> </p><p> </p><p> </p><p>In the meantime, NHS England is currently consulting on a new service specification for the genetic/genomic laboratory services which is its direct commissioning responsibility. A procurement process will take place following the consultation. The consultation, including the proposed service specification, can be accessed at:</p><p> </p><p> </p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/genomic-laboratories" target="_blank">https://www.engage.england.nhs.uk/consultation/genomic-laboratories</a></p><p> </p><p> </p><p> </p><p>The Department is not aware of any such targets for introducing and funding diagnostics testing. NHS England do not agree that there has been reduced access to molecular testing for cancer, but accept that there has always been variation.</p><p> </p><p> </p><p> </p><p>The Department holds NHS England to account for achieving its objectives in a number of ways. The Mandate to NHS England, published by the Department, sets out its core objectives. NHS England must publish an annual business plan, and report on progress against its objectives at the end of each year. At the end of each year, the Secretary of State also publishes an assessment of NHS England’s performance. The Secretary of State holds regular accountability meetings with NHS England based on an assessment of performance against the Mandate and its wider functions.</p><p> </p> answering member printed Earl Howe grouped question UIN HL4084 HL4085 HL4086 HL4087 question first answered 26/01/2015 12:24:07 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

173012

	registered interest
	date	12/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what discussions they have had with (1) NHS England, and (2) other bodies, to ensure that they meet their deadline to implement the molecular diagnostics policy and service specifications in cancer.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL4084
	answer	answer is ministerial correction date of answer 26/01/2015 answer text <p><em>Improving Outcomes: a Strategy for Cancer</em> (Department of Health, 2011) did include a specific commitment to develop a commissioning and funding structure which would enable the efficient delivery of high quality molecular diagnostic testing through centres of excellence. The first phase of this work included the establishment of the Human Genomics Strategy Group (HGSG). NHS England drew upon the work of the HGSG, specifically the report <em>Building on our Inheritance; Genomic technology in healthcare</em> (2012), in the production of the proposed genetics laboratory service specification.</p><p> </p><p> </p><p> </p><p>Since 2011, the field of genetic medicine and genomics has progressed rapidly with many molecular tests now available locally. Further work is underway to better understand the specific responsibilities of NHS England as a direct commissioner of specialised services, clarify the legacy arrangements of how such tests are currently commissioned and ensure alignment with the National Tariff payment rules. This may highlight the need to develop specific commissioning policies, or undertake other commissioning interventions, that will support the continued diffusion of such technology across the National Health Service.</p><p> </p><p> </p><p> </p><p>Molecular diagnostics for cancer is the responsibility of a range of commissioners, and historically many of these tests have been funded in a number of different ways including by industry (i.e., have been free to the NHS). The legacy work may highlight a need for NHS England to undertake commissioning interventions, which could include the development of specific commissioning policies or pricing work.</p><p> </p><p> </p><p> </p><p>Funding for these molecular tests is complex. At this stage, the earliest opportunity for changes to be made to the National Tariff, should such action be thought to be necessary, is now 2016-17 with consultation on any proposals being launched in summer 2015.</p><p> </p><p> </p><p> </p><p>In the meantime, NHS England is currently consulting on a new service specification for the genetic/genomic laboratory services which is its direct commissioning responsibility. A procurement process will take place following the consultation. The consultation, including the proposed service specification, can be accessed at:</p><p> </p><p> </p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/genomic-laboratories" target="_blank">https://www.engage.england.nhs.uk/consultation/genomic-laboratories</a></p><p> </p><p> </p><p> </p><p>The Department is not aware of any such targets for introducing and funding diagnostics testing. NHS England do not agree that there has been reduced access to molecular testing for cancer, but accept that there has always been variation.</p><p> </p><p> </p><p> </p><p>The Department holds NHS England to account for achieving its objectives in a number of ways. The Mandate to NHS England, published by the Department, sets out its core objectives. NHS England must publish an annual business plan, and report on progress against its objectives at the end of each year. At the end of each year, the Secretary of State also publishes an assessment of NHS England’s performance. The Secretary of State holds regular accountability meetings with NHS England based on an assessment of performance against the Mandate and its wider functions.</p><p> </p> answering member printed Earl Howe grouped question UIN HL4083 HL4085 HL4086 HL4087 question first answered 26/01/2015 12:24:07 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

173013

	registered interest
	date	12/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what discussions they have had with (1) NHS England, and (2) other bodies, to ensure that there is sufficient funding in place to cover diagnostics testing for cancer.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL4085
	answer	answer is ministerial correction date of answer 26/01/2015 answer text <p><em>Improving Outcomes: a Strategy for Cancer</em> (Department of Health, 2011) did include a specific commitment to develop a commissioning and funding structure which would enable the efficient delivery of high quality molecular diagnostic testing through centres of excellence. The first phase of this work included the establishment of the Human Genomics Strategy Group (HGSG). NHS England drew upon the work of the HGSG, specifically the report <em>Building on our Inheritance; Genomic technology in healthcare</em> (2012), in the production of the proposed genetics laboratory service specification.</p><p> </p><p> </p><p> </p><p>Since 2011, the field of genetic medicine and genomics has progressed rapidly with many molecular tests now available locally. Further work is underway to better understand the specific responsibilities of NHS England as a direct commissioner of specialised services, clarify the legacy arrangements of how such tests are currently commissioned and ensure alignment with the National Tariff payment rules. This may highlight the need to develop specific commissioning policies, or undertake other commissioning interventions, that will support the continued diffusion of such technology across the National Health Service.</p><p> </p><p> </p><p> </p><p>Molecular diagnostics for cancer is the responsibility of a range of commissioners, and historically many of these tests have been funded in a number of different ways including by industry (i.e., have been free to the NHS). The legacy work may highlight a need for NHS England to undertake commissioning interventions, which could include the development of specific commissioning policies or pricing work.</p><p> </p><p> </p><p> </p><p>Funding for these molecular tests is complex. At this stage, the earliest opportunity for changes to be made to the National Tariff, should such action be thought to be necessary, is now 2016-17 with consultation on any proposals being launched in summer 2015.</p><p> </p><p> </p><p> </p><p>In the meantime, NHS England is currently consulting on a new service specification for the genetic/genomic laboratory services which is its direct commissioning responsibility. A procurement process will take place following the consultation. The consultation, including the proposed service specification, can be accessed at:</p><p> </p><p> </p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/genomic-laboratories" target="_blank">https://www.engage.england.nhs.uk/consultation/genomic-laboratories</a></p><p> </p><p> </p><p> </p><p>The Department is not aware of any such targets for introducing and funding diagnostics testing. NHS England do not agree that there has been reduced access to molecular testing for cancer, but accept that there has always been variation.</p><p> </p><p> </p><p> </p><p>The Department holds NHS England to account for achieving its objectives in a number of ways. The Mandate to NHS England, published by the Department, sets out its core objectives. NHS England must publish an annual business plan, and report on progress against its objectives at the end of each year. At the end of each year, the Secretary of State also publishes an assessment of NHS England’s performance. The Secretary of State holds regular accountability meetings with NHS England based on an assessment of performance against the Mandate and its wider functions.</p><p> </p> answering member printed Earl Howe grouped question UIN HL4083 HL4084 HL4086 HL4087 question first answered 26/01/2015 12:24:07 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

173014

	registered interest
	date	12/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they are taking to standardise access to funding for cancer-related molecular testing.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL4086
	answer	answer is ministerial correction date of answer 26/01/2015 answer text <p><em>Improving Outcomes: a Strategy for Cancer</em> (Department of Health, 2011) did include a specific commitment to develop a commissioning and funding structure which would enable the efficient delivery of high quality molecular diagnostic testing through centres of excellence. The first phase of this work included the establishment of the Human Genomics Strategy Group (HGSG). NHS England drew upon the work of the HGSG, specifically the report <em>Building on our Inheritance; Genomic technology in healthcare</em> (2012), in the production of the proposed genetics laboratory service specification.</p><p> </p><p> </p><p> </p><p>Since 2011, the field of genetic medicine and genomics has progressed rapidly with many molecular tests now available locally. Further work is underway to better understand the specific responsibilities of NHS England as a direct commissioner of specialised services, clarify the legacy arrangements of how such tests are currently commissioned and ensure alignment with the National Tariff payment rules. This may highlight the need to develop specific commissioning policies, or undertake other commissioning interventions, that will support the continued diffusion of such technology across the National Health Service.</p><p> </p><p> </p><p> </p><p>Molecular diagnostics for cancer is the responsibility of a range of commissioners, and historically many of these tests have been funded in a number of different ways including by industry (i.e., have been free to the NHS). The legacy work may highlight a need for NHS England to undertake commissioning interventions, which could include the development of specific commissioning policies or pricing work.</p><p> </p><p> </p><p> </p><p>Funding for these molecular tests is complex. At this stage, the earliest opportunity for changes to be made to the National Tariff, should such action be thought to be necessary, is now 2016-17 with consultation on any proposals being launched in summer 2015.</p><p> </p><p> </p><p> </p><p>In the meantime, NHS England is currently consulting on a new service specification for the genetic/genomic laboratory services which is its direct commissioning responsibility. A procurement process will take place following the consultation. The consultation, including the proposed service specification, can be accessed at:</p><p> </p><p> </p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/genomic-laboratories" target="_blank">https://www.engage.england.nhs.uk/consultation/genomic-laboratories</a></p><p> </p><p> </p><p> </p><p>The Department is not aware of any such targets for introducing and funding diagnostics testing. NHS England do not agree that there has been reduced access to molecular testing for cancer, but accept that there has always been variation.</p><p> </p><p> </p><p> </p><p>The Department holds NHS England to account for achieving its objectives in a number of ways. The Mandate to NHS England, published by the Department, sets out its core objectives. NHS England must publish an annual business plan, and report on progress against its objectives at the end of each year. At the end of each year, the Secretary of State also publishes an assessment of NHS England’s performance. The Secretary of State holds regular accountability meetings with NHS England based on an assessment of performance against the Mandate and its wider functions.</p><p> </p> answering member printed Earl Howe grouped question UIN HL4083 HL4084 HL4085 HL4087 question first answered 26/01/2015 12:24:07 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath